Century Therapeutics (IPSC) catalysts

Upcoming FDA decisions and readouts we track for Century Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 07 Oct 2026

FreeBioList tracks 1 upcoming catalyst for Century Therapeutics (IPSC, listed on Nasdaq). It concerns CNTY-813 (Type 1 diabetes (iPSC-derived islet cells)).

First on the list: the Phase 1 readout for CNTY-813 (Type 1 diabetes (iPSC-derived islet cells)), guided by the company to H2 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: IPSC
Next catalyst: H2 2027
Type: Phase 1 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Century Therapeutics IPSC · Nasdaq	CNTY-813	Type 1 diabetes (iPSC-derived islet cells)	H2 2027 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "Initial safety and early efficacy data from the first-in-human CNTY-813 study are anticipated in the second half of 2027." The IND is due Q4 2026, so the study hasn't started yet. Source: 8-K exhibit 99.1, filed 02 Oct 2026 · verified 07 Oct 2026

Companies working on related conditions

Fractyl Health (GUTS)Type 2 diabetes (pancreatic gene therapy); Post-GLP-1 weight maintenance — 6-month randomised data; Post-GLP-1 weight maintenance — one-year data
Structure Therapeutics (GPCR)Type 2 diabetes with obesity or overweight; Obesity; Obesity and overweight